About Potentiam
Potentiam uses artificial intelligence to find targets for new medicines. Its platforms are designed to identify and develop those targets.
Potentiam is based in Irving, Texas. Peppi Prasit is chief executive officer. Bruce Beutler is chairman and president. He also serves as secretary and sole director.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Nov 3, 2026 | Nov 16, 2026 | $250,000target not set | 1 | $250K | Options, Securities on exercise, Simple Agreement for Future Equity (SAFE)Rule 506(b) | Form D ↗ |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Potentiam's Form D filed Nov 16, 2026.
Why Investors Backed Potentiam
Potentiam's view is that some therapeutic targets remain hard to find. Its AI-powered platforms are designed to identify and develop new targets. [1]
We wrote this summary from public statements by Potentiam and its investors. It is not investment advice.
Sources
- CompanyPotentiam website · linked above ↑
- SECPotentiam Form D, filed 2026-11-16 · linked above ↑
- SECPotentiam Biosciences, Inc. filing history
